-
公开(公告)号:US20080010700A1
公开(公告)日:2008-01-10
申请号:US11823825
申请日:2007-06-28
CPC分类号: C12N15/8286 , C07K14/415 , C12N9/14 , C12N9/18 , C12N15/8242 , Y02A40/162 , Y10S930/13
摘要: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
摘要翻译: 公开了修饰的蛋白质,其在显示减少或消除的变应原性的同时保持酶促和杀虫活性。 鉴定结合抗patatin抗体的表位,并通过定点诱变去除。 观察到酪氨酸通常有助于patatin蛋白的过敏性质。 观察到去除糖基化位点以减少或消除抗体结合。 还公开了具有重排的氨基酸序列同时保留酶活性的泛珠菌素。 脱敏蛋白和泛醇蛋白可用作杀虫剂,作为营养补充剂,以及作为免疫治疗剂。
-
公开(公告)号:US20060206962A1
公开(公告)日:2006-09-14
申请号:US11220856
申请日:2005-09-07
CPC分类号: C12N15/8286 , C07K14/415 , C12N9/14 , C12N9/18 , C12N15/8242 , Y02A40/162 , Y10S930/13
摘要: Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding. Permuteins are also disclosed which have a rearranged amino acid sequence while retaining enzymatic activity. Deallergenized proteins and permuteins can be used as insecticidal materials, as nutritional supplements, and as immunotherapeutic agents.
摘要翻译: 公开了修饰的蛋白质,其在显示减少或消除的变应原性的同时保持酶促和杀虫活性。 鉴定结合抗patatin抗体的表位,并通过定点诱变去除。 观察到酪氨酸通常有助于patatin蛋白的过敏性质。 观察到去除糖基化位点以减少或消除抗体结合。 还公开了具有重排的氨基酸序列同时保留酶活性的泛珠菌素。 脱敏蛋白和泛醇蛋白可用作杀虫剂,作为营养补充剂,以及作为免疫治疗剂。
-
公开(公告)号:US20140274922A1
公开(公告)日:2014-09-18
申请号:US14025766
申请日:2013-09-12
申请人: Leslie van der Meulen , Daniel Fleischer , Michelle L. Collins , James Astwood , Jeffrey Gerard Hippler , Andrew Thompson
发明人: Leslie van der Meulen , Daniel Fleischer , Michelle L. Collins , James Astwood , Jeffrey Gerard Hippler , Andrew Thompson
IPC分类号: A61K31/201 , A61K31/683 , A61K31/7012 , A61K31/202 , A61K31/231
CPC分类号: A23L17/60 , A21D2/165 , A23D9/00 , A23L2/04 , A23L33/105 , A23L33/115 , A23L33/12 , A23V2002/00 , A23V2200/308 , A23V2200/326 , A23V2200/328 , A23V2250/187 , A23V2250/1876 , A23V2250/202 , A61K31/20 , A61K31/201 , A61K31/202 , A61K31/231 , A61K31/661 , A61K31/683 , A61K31/7012 , A61K31/7028 , A61K36/02 , C11B3/001 , C11C1/02 , C11C3/08 , C12N15/8247 , C12P7/6427 , A61K2300/00 , A23V2250/1868
摘要: Provided herein are exemplary algal omega 7 compositions, including algal fatty acid compositions comprising by dry weight from about approximately 0.5% to about approximately 99% C16:1 n7 palmitoleic acid (POA). Such algal compositions may also include (either individually or any combination of) by dry weight: from about approximately 0% to about approximately 20% saturated fatty acids; from about approximately 0% to about approximately 99% arachidonic acid; from about approximately 0% to about 99% docosahexaenoic acid; and/or from about approximately 0% to about approximately 99% eicosapentaenoic acid. Further exemplary algal fatty acid compositions may include by dry weight about approximately 90% POA, less than about approximately 20% saturated fatty acids, less than about approximately 10% ARA, substantially no DHA, and less than about approximately 10% EPA.
摘要翻译: 本文提供了示例性的藻类ω7组合物,包括由干重约约0.5%至约99%C16:1n7棕榈油酸(POA)组成的藻类脂肪酸组合物。 这样的藻类组合物还可包括干燥重量的(单独或任意组合):约0%至约约20%的饱和脂肪酸; 约0%至约99%的花生四烯酸; 约0%至约99%的二十二碳六烯酸; 和/或约约0%至约99%的二十碳五烯酸。 进一步示例性的藻类脂肪酸组合物可包括干重约约90%的POA,小于约约20%的饱和脂肪酸,小于约约10%的ARA,基本上不含DHA和小于约10%的EPA。
-
公开(公告)号:US20140271706A1
公开(公告)日:2014-09-18
申请号:US14025772
申请日:2013-09-12
IPC分类号: A23L1/30 , A61K31/202 , A61K31/232 , A61K31/661 , A61K31/7028 , A61K36/02 , A61K31/201
CPC分类号: A23L17/60 , A21D2/165 , A23D9/00 , A23L2/04 , A23L33/105 , A23L33/115 , A23L33/12 , A23V2002/00 , A23V2200/308 , A23V2200/326 , A23V2200/328 , A23V2250/187 , A23V2250/1876 , A23V2250/202 , A61K31/20 , A61K31/201 , A61K31/202 , A61K31/231 , A61K31/661 , A61K31/683 , A61K31/7012 , A61K31/7028 , A61K36/02 , C11B3/001 , C11C1/02 , C11C3/08 , C12N15/8247 , C12P7/6427 , A61K2300/00 , A23V2250/1868
摘要: Provided herein are exemplary compositions, products, and capsules utilizing POA, EPA, blends of POA and EPA, total algal oil compositions, and/or whole biomass compositions in methods of inhibiting inflammation including in cardiovascular disease, diabetes, obesity, stroke, metabolic syndromes, dementia, Alzheimer's disease, and/or cancer. The exemplary compositions, products, and capsules may be orally, topically, intravenously, and/or subcutaneously administered. The exemplary compositions herein may be used as feed, food, food supplements, beverages, beverage supplements, nutritional products, products for athletic performance, pharmaceutical products, and/or medical products for mammalian use, including humans.
摘要翻译: 本文提供了在抑制炎症的方法中使用POA,EPA,POA和EPA的混合物,总藻类组合物和/或整个生物质组合物的示例性组合物,产品和胶囊,包括在心血管疾病,糖尿病,肥胖症,中风,代谢综合征 ,痴呆,阿尔茨海默病和/或癌症。 示例性组合物,产品和胶囊可以是口服,局部,静脉内和/或皮下施用的。 本文的示例性组合物可用作饲料,食品,食品添加剂,饮料,饮料补充剂,营养产品,用于运动表现的产品,药物产品和/或哺乳动物使用的医疗产品,包括人类。
-
公开(公告)号:US09445619B2
公开(公告)日:2016-09-20
申请号:US14025772
申请日:2013-09-12
IPC分类号: A23L1/30 , A61K31/201 , A61K31/202 , A61K31/661 , A61K31/7028 , A61K36/02 , C12N15/82 , C12P7/64 , A61K31/231 , A61K31/683 , A61K31/7012 , C11C1/02 , C11B3/00 , C11C3/08 , A23D9/00 , A21D2/16 , A61K31/20 , A23L1/337 , A23L2/04
CPC分类号: A23L17/60 , A21D2/165 , A23D9/00 , A23L2/04 , A23L33/105 , A23L33/115 , A23L33/12 , A23V2002/00 , A23V2200/308 , A23V2200/326 , A23V2200/328 , A23V2250/187 , A23V2250/1876 , A23V2250/202 , A61K31/20 , A61K31/201 , A61K31/202 , A61K31/231 , A61K31/661 , A61K31/683 , A61K31/7012 , A61K31/7028 , A61K36/02 , C11B3/001 , C11C1/02 , C11C3/08 , C12N15/8247 , C12P7/6427 , A61K2300/00 , A23V2250/1868
摘要: Provided herein are exemplary compositions, products, and capsules utilizing POA, EPA, blends of POA and EPA, total algal oil compositions, and/or whole biomass compositions in methods of inhibiting inflammation including in cardiovascular disease, diabetes, obesity, stroke, metabolic syndromes, dementia, Alzheimer's disease, and/or cancer. The exemplary compositions, products, and capsules may be orally, topically, intravenously, and/or subcutaneously administered. The exemplary compositions herein may be used as feed, food, food supplements, beverages, beverage supplements, nutritional products, products for athletic performance, pharmaceutical products, and/or medical products for mammalian use, including humans.
摘要翻译: 本文提供了在抑制炎症的方法中使用POA,EPA,POA和EPA的混合物,总藻类组合物和/或整个生物质组合物的示例性组合物,产品和胶囊,包括在心血管疾病,糖尿病,肥胖症,中风,代谢综合征 ,痴呆,阿尔茨海默病和/或癌症。 示例性组合物,产品和胶囊可以是口服,局部,静脉内和/或皮下施用的。 本文的示例性组合物可用作饲料,食品,食品添加剂,饮料,饮料补充剂,营养产品,用于运动表现的产品,药物产品和/或哺乳动物使用的医疗产品,包括人类。
-
6.
公开(公告)号:US20140275596A1
公开(公告)日:2014-09-18
申请号:US14025756
申请日:2013-09-12
IPC分类号: C11B3/00
CPC分类号: A23L17/60 , A21D2/165 , A23D9/00 , A23L2/04 , A23L33/105 , A23L33/115 , A23L33/12 , A23V2002/00 , A23V2200/308 , A23V2200/326 , A23V2200/328 , A23V2250/187 , A23V2250/1876 , A23V2250/202 , A61K31/20 , A61K31/201 , A61K31/202 , A61K31/231 , A61K31/661 , A61K31/683 , A61K31/7012 , A61K31/7028 , A61K36/02 , C11B3/001 , C11C1/02 , C11C3/08 , C12N15/8247 , C12P7/6427 , A61K2300/00 , A23V2250/1868
摘要: Provided herein are exemplary algal fatty acid compositions comprising by dry weight approximately 0.5% to approximately 99% C20:5 n3 Eicosapentaenoic acid (EPA) and approximately 0.5% to approximately 99% C16:1 n7 palmitoleic acid (POA). Further exemplary algal fatty acid compositions may comprise (in addition to the above) one or more of the following by dry weight: between approximately 0% and 99% arachidonic acid; between approximately 0% and 99% docosahexaenoic acid; and/or less than approximately 10% saturated fatty acids (including 0% saturated fatty acids or substantially saturated fatty acid free). Further exemplary saturated fatty acyl moiety-rich algal compositions may be in a form of an ethyl ester (EE), a mono, di- or triacylglycerol (MAG, DAG, TAG), a phospholipid (PL), a galactolipid (GL), free fatty Acid (FFA), or a sulfoquinovosyl diacylglycerol (SQDG).
摘要翻译: 本文提供了示例性的藻类脂肪酸组合物,其包含干重约0.5%至约99%的C20:5N3二十碳五烯酸(EPA)和约0.5%至约99%的C16:1n7棕榈油酸(POA)。 进一步示例性的藻类脂肪酸组合物可以包含(除了上述之外)干燥中的一种或多种以下:花生四烯酸在约0%至99%之间; 约0%至99%之间的二十二碳六烯酸; 和/或小于约10%的饱和脂肪酸(包括0%饱和脂肪酸或基本上饱和的无脂肪酸)。 进一步示例性的饱和脂肪酰基部分富含藻类组合物可以是乙酯(EE),单,二或三酰基甘油(MAG,DAG,TAG),磷脂(PL),半乳糖脂(GL), 游离脂肪酸(FFA)或磺基奎诺糖基二酰基甘油(SQDG)。
-
-
-
-
-